Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice.

Jiahong Sun,Joshua Yang,Kathrine Whitman, Charlene Zhu,David H Cribbs,Ruben J Boado,William M Pardridge,Rachita K Sumbria

Alzheimer's & Dementia: Translational Research & Clinical Interventions（2019）

引用 13|浏览16

暂无评分

摘要

•Chimeric monoclonal antibody against the mouse TfR (cTfRMAb)-erythropoietin (EPO) is a brain-penetrating IgG-EPO fusion protein.•Chronic treatment with cTfRMAb-EPO does not alter hematology indices in APP/PS1 mice.•Equimolar dose of recombinant human EPO significantly alters hematologic indices in APP/PS1 mice.•Both cTfRMAb-EPO and recombinant human EPO reduce amyloid beta load in APP/PS1 mice.•cTfRMAb-EPO selectively reduces amyloid beta (1–42) and increases synaptophysin in APP/PS1 mice.

查看译文

关键词

Blood-brain barrier,Safety,Hematology,Erythropoietin,Alzheimer's disease,Transferrin receptor,Monoclonal antibody

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要